rectal cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) 18-79 years old, male or female; 2) Diagnosed with locally advanced rectal cancer (stage II/III) from January 2023 to December 2025, intending to receive neoadjuvant chemoradiotherapy and surgical treatment , accepting long-term follow-up; 3) Pelvic FAPI-PET/MRI scan and other imaging examinations are performed within 14 days before radiotherapy and chemotherapy; 4) Signed the informed consent form;
Exclusion criteria
Exclusion criteria: 1) Patients who have received tumor treatments such as radiotherapy, chemotherapy, immunotherapy, etc. before surgery; 2) The patient has contraindications to surgery or radiotherapy, or refuses treatment; 3) Women who are trying to get pregnant, pregnant and lactating; 4) Patients suffering from claustrophobia or other psychiatric disorders; 5) Patients with other malignant tumors or distant metastases; 6) Other cases in which the investigator deems it inappropriate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy of FAPI-PET/MRI for the evaluation of lymph node metastasis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Accuracy of FAPI-PET/MRI for the evaluation of invasion of the mesenteric fascia;Accuracy of FAPI-PET/MRI for the evaluation of invasion of the extramural vasculature;Feasibility of FAPI-PET/MRI for the assessment of immune cell infiltration in tumor tissue; | — |
Countries
China
Contacts
the First Affiliated Hospital of Zhejiang University School of Medicine